|
Jacobson Pharma Launches Smartfish Health Nutrition Products from Norway in Greater China and Asia Pacific Region
HONG KONG, Nov 12, 2019 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines, announced the launch of Smartfish's health nutrition range of products in Greater China (including Mainland China, Hong Kong, Macau and Taiwan) and Asia under an exclusive distribution agreement with Smartfish AS, a branded health nutrition company incorporated in Norway.
 | | Photo Caption (1): Smartfish products for the consumer health nutrition range; Photo Caption (2): Smartfish is the official supplier of sports nutrition drinks to sports clubs and national teams, including English Premier League Tottenham Hotspurs Football Club |
According to the agreement, the Group has an in-licensed right for 10 years to distribute and market Smartfish's consumer health products in Greater China and the Asia Pacific Region, covering four product ranges, namely "Smartfish Recharge" for sports nutrition, "Smartfish Resolve" for improving metabolic health and diabetes care, "Smartfish Reflect" for promoting adults' brain health and cognitive function, and "Smartfish Cream" for benefiting children's brain development
Built upon a patented emulsion technology and clinically substantiated, Smartfish's Omega-3-enhanced nutritional drinks and emulsion products complement the fast-growing medical and consumer nutrition markets with products of evidence-based health benefits.
Differentiated from standard fish oil supplements, Smartfish's emulsion carries high levels of Omega 3 fatty acids, in synergy with other nutrients, that can produce the potentiating anti-inflammatory effects to deliver various health benefits . It can also ensure a tasty delivery of nutrients by protecting Omega-3 fatty acids, which are rich in fish oil, from oxidizing and forming the rancid taste. The products are clinically tested, and all health benefit claims for Smartfish products are supported by rigorous science.
Smartfish's products range provides health nutrition for the elderly and the young, medical nutrition for chronic disease patients, and sports nutrition for athletes. Smartfish has established itself as a trusted nutritional source for professional athletes worldwide being the official supplier of sports nutrition drinks to sports clubs and national teams, which include English Premier League Tottenham Hotspurs Football Club and Norwegian Nordic Combined National Team of Skiing.
Jacobson Pharma's strategic collaboration with Smartfish also included a shareholding investment of 9.04% of Smartfish's issued capital made in July 2019, which is expected to forge a stronger partnership and platform for both companies on exploring potential business cooperation in the high growing consumer health nutrition market in the future.
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, comments, "We welcome Smartfish's nutrition products with well-documented potency to our consumer health product portfolio. The health nutrition market has witnessed strong growth driven by the greater inclination towards self-care and health problems prevention, alongside a growing aged population and increase in disposable income. Through this collaboration, Jacobson Pharma has primed itself to collaborate with Smartfish in exploiting the latent demand for clinically substantiated health nutrition products to meet different lifestyle and healthcare needs among consumers in Greater China and the Asia Pacific Region."
About Jacobson Pharma Corporation Limited (Stock Code: 2633) Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims to enrich its portfolio through addition of high value-added products covering sterile injections, oncology products as well as orphan drugs and biosimilars. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
About Smartfish AS Smartfish is a company incorporated in Norway which focuses on research & development, production and marketing of advanced, science-based and clinically documented nutritional products. Smartfish provides unique nutritional solutions for both medical use and consumer health. Its nutrition products are based on a proprietary emulsion technology that enables the effective delivery of high levels of Omega 3 fatty acids, whey protein and other nutrients. Smartfish has a number of ongoing clinical development projects and studies in the pipeline in close collaboration with renowned researchers and institutions around the world. The company was founded in 2001 and is now headquartered in Oslo, Norway with an operating subsidiary in Lund, Sweden. Smartfish's main shareholders include Investinor (a Norwegian-based fund) and Industrifonden (a Nordic fund). Learn more on www.smartfishnutrition.com.
For media enquiries, please contact: Strategic Financial Relations Limited Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk Stephanie Liu Tel: (852) 2864 4852 Email: stephanie.liu@sprg.com.hk Tika Lum Tel: (852) 2864 4806 Email: tika.lum@sprg.com.hk Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited Sectors: Daily Finance, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Lexus World Premieres Lexus LFA Concept BEV Sports Car Dec 05, 2025 19:13 JST
|  TOYOTA GAZOO Racing World Premieres GR GT & GR GT3 Dec 05, 2025 18:58 JST
|  TOYOTA GAZOO Racing and Lexus Hold World Premiere of GR GT, GR GT3, and Lexus LFA Concept Dec 05, 2025 18:24 JST
|  World's First General Design Approval (GDA) for Developed Steel and Post-Weld Heat Treatment (PWHT) Exemption based on ECA for Low-pressure Liquefied CO2 Tank made of KF460 steel Dec 05, 2025 18:17 JST
|  Hitachi at CES 2026: Building a Harmonized Society Through Technology Dec 04, 2025 19:40 JST
|  Fujitsu and Scaleway partner to accelerate European sustainable transformation and data sovereignty with FUJITSU-MONAKA CPU-based AI inference Dec 04, 2025 19:08 JST
|  NEC Orchestrating Future Fund Invests in PopID, Inc. to Accelerate Global Expansion of Biometric Payment Solutions and Launch a Strategic Collaboration Dec 04, 2025 18:52 JST
|  Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 Dec 04, 2025 18:36 JST
|  The 26th Hong Kong Forum marks successful completion Dec 03, 2025 22:44 JST
|  New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF Dec 03, 2025 18:19 JST
|  Mitsubishi Motors Launches the All-New Destinator in Vietnam Dec 03, 2025 18:00 JST
|  Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15 Dec 03, 2025 11:30 JST
|  Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 Dec 03, 2025 00:01 JST
|  NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI Dec 02, 2025 23:43 JST
|  Fujitsu develops new technology to support human-robot collaboration Dec 02, 2025 23:26 JST
|  Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks Dec 02, 2025 22:55 JST
|  Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms Dec 01, 2025 23:04 JST
|  Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials Dec 01, 2025 22:43 JST
|  Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology Dec 01, 2025 22:14 JST
|  Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan Nov 28, 2025 23:00 JST
|
More Latest Release >>
|